NGM Biopharmaceuticals Inc (NASDAQ:NGM)
| 15.61 Delayed Data As of Sep 23 |  -1.15 / -6.87%Today’s Change | 8.81 Today|||52-Week Range 23.95 | -15.58% Year-to-Date |
Latest NGM News | Press Releases
| NGM Bio Aldafermin Data, And Other News: The Good, Bad And Ugly Of Biopharma Sep 06 / Seeking Alpha - Paid Partner Content | NGM Bio's aldafermin shows positive effect in NASH patients with advanced disease Aug 31 / Seeking Alpha - Paid Partner Content |
| NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow Aug 31 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 16.74 |
| Today’s open | 16.76 |
| Day’s range | 15.50 - 16.76 |
| Volume | 242,527 |
| Average volume (3 months) | 233,803 |
| Market cap | $1.3B |
Data as of 3:59pm ET, 09/23/2020
Growth & Valuation
| Earnings growth (last year) | -11,244.00% |
| Earnings growth (this year) | -72.14% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -4.71% |
| P/E ratio | NM |
| Price/Sales | 8.98 |
| Price/Book | 3.87 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RYTMRhythm Pharmaceutica... | -0.81 | -3.10% |
| STOKStoke Therapeutics I... | -0.86 | -2.51% |
| ADVMAdverum Biotechnolog... | -0.60 | -5.05% |
| RCUSArcus Biosciences In... | -1.04 | -5.56% |
Data as of 3:59pm ET, 09/23/2020
Financials
| Next reporting date | November 17, 2020 |
| EPS forecast (this quarter) | -$0.37 |
| Annual revenue (last year) | $103.5M |
| Annual profit (last year) | -$42.8M |
| Net profit margin | -41.33% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters South San Francisco, California |
Forecasts
